|
| A retrospective study of Fuzheng Jiedu Quzhuo prescription combined with EC chemotherapy in patients with extensive-stage small cell lung cancer |
| Hits 12 Download times 7 Received:August 10, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.11.03 |
| Key Words
Fuzheng Jiedu Quzhuo prescription;extensive-stage small cell lung cancer;etoposide;carboplatin;lymphocyte subsets;inflammatory cytokines |
| Author Name | Affiliation | | YANG Peiying | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | HE Jiaying | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | ZHANG Yao | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | KONG Fanming | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | ZHU Jinli | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | JIA Yingjie | Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China |
|
| Abstract
|
| [Objective] To observe the effect of Fuzheng Jiedu Quzhuo prescription combined with chemotherapy on the immune function and clinical efficacy of patients with Extensive Stage Small Cell Lung Cancer(ES-SCLC). [Methods] A retrospective study was conducted to collect 60 patients with extensive-stage small cell lung cancer who met the inclusion criteria and were hospitalized in the department of oncology of The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from January 1,2022 to June 30,2023 through the electronic medical record system. According to whether the patients were treated with Fuzheng Jiedu Quzhuo prescription during chemotherapy,they were divided into 30 cases in the exposed group and 30 cases in the non-exposed group. To observe the effects of Fuzheng Jiedu Quzhuo prescription combined with chemotherapy on progression-free survival,objective remission rate,lymphocyte subsets,cytokines,traditional Chinese medicine(TCM) syndromes,KPS scores and chemotherapy-related adverse reactions in ES-SCLC patients. [Results] In the long-term efficacy,the mPFS was significantly prolonged between the exposed group comparing with the non-exposed group(P<0.05). There was no significant difference in ORR in the short-term efficacy(P>0.05). In terms of immune function,compared with the non-exposed group,CD3+,CD4+ T lymphocytes and NK cells in the exposed group increased significantly,while Treg cells decreased,and the difference was statistically significant(P<0.05). The comparison of the effects of inflammatory cytokines expression showed that the serum levels of IL-4,IL-6 and IL-10 were significantly lower in the exposed group than in the non-exposed group after treatment,and the IFN-γ exposed group was higher than that in the non-exposed group,and the difference was statistically significant(P<0.05). In terms of clinical symptoms,compared with the non-exposure group,the TCM syndrome score and KPS score of the exposed group were significantly improved,and the chemotherapy-related leukopenia and gastrointestinal reactions were significantly reduced,and the difference was statistically significant(P<0.05). [Conclusion] Compared with chemotherapy alone,Fuzheng Jiedu Quzhuo prescription combined with chemotherapy can improve the immune function of ES-SCLC patients,increase the efficiency of adjuvant chemotherapy and reduce toxicity,and improve the quality of life of patients to a certain extent. |
|
|
|
|
|
|
|
